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The uncontrolled growth of tumor
cells sets them apart from normal
cells. Current chemotherapy hits the
primary difference — an increased
level of proliferation — with a
particularly blunt sledgehammer.
The associated toxicity and collateral
damage is massive. 
The idea of using the immune
system as a more exact weapon has
been around since 1893, when William
Coley observed cancer regression after
erysipelas infection. Perhaps, the
thought goes, the immune system can
be directed against individual
molecular differences present in
tumor cells. Early success in animal
models was followed by a failure to
cross-protect — animals had to be
immunized with material prepared
from their own tumors — and
suspicions that animal models were a
poor simulation of human cancers. 
Slowly the field of cancer
immunotherapy has revived itself.
The search for tumor-specific antigens
has been long and hard, and many of
the therapies being tested now are
tissue- rather than tumor-specific. But
renewed hope is coming from the use
of genomics to define tumor
differences. “I think the time is right
for these therapies to be taken to the
clinic,” says Michael Longenecker,
senior vice president for research and
development at Biomira Inc.
(Edmonton, Alberta, Canada). 
The number of companies
searching for tumor-specific antigens
is ever-increasing (Table 1). But
Pramod Srivastava, an immunologist
at the University of Connecticut and
the scientific founder of Antigenics
L.L.C. (New York, NY), is spurning
the definition of tumor-specific
antigens. “There is no reason to
believe that those [tumor-specific]
molecules exist,” he says. Srivastava
is sticking with the original
observation that protection is often
restricted to the animal from which
the antigenic material was derived.
His proposal is a personalized
therapy based on, of all things, heat-
shock proteins.
A nasty shock
Srivastava came to immunology with a
distinctly different perspective. While
others were sorting macrophages and
T cells, and scanning with antibodies,
he was tackling cancer
immunotherapy like a good
biochemist. He fractionated. But
when he whittled down his protective
fractions to a single protein he got a
nasty surprise: the magic antigen, over
and over again, was a heat-shock
protein (hsp). Hsps are well known
for their roles in protein folding and
recovery from stress, but not for
growth promotion and carcinogenesis.
Could Srivastava have been so wrong?
If every cancer is different, why
not try a personalized vaccine?
“It was extremely depressing,”
he says. “I entered the winter of my
discontent, not knowing where to go
from there. I kept looking for where
I had gone wrong.” Quickly he
looked for, and failed to find,
variations between hsp genes in
normal and cancer cells. Hsps were
such unlikely candidate tumor
promoters that “it was clear there
had to be a contaminant,” he says.
But nothing was visible on gels. “By
deduction I argued it was peptides,”
says Srivastava. “At the time I was
attacked a lot because I had no data
about the peptides.”
But the data came. In 1993,
Srivastava found that the critical
ingredient was, indeed, peptides.
Most of the peptides are identical
between normal and cancer cells, but
a critical few differ. Srivastava believes
that the high mutation rate in cancer
cells generates random changes in a
random assortment of proteins. Most
of the changes are not related to the
process of transformation and are
unique to each cancer. But rare
divergent peptides, when bound to
and presented by hsps, can be
detected as immunogenic by immune
cells. This presentation route is potent
because antigen-presenting cells have
specific receptors for the hsps and, as
Srivastava found in 1995, the cells’
intracellular trafficking directs the
peptides onto products of the major
histocompatibility complex (MHC),
ready for display to the rest of the
immune system.
Presumably this complicated
pathway has not evolved for the
benefit of cancer immunologists.
Rather it may be a primitive early
warning system — the original signal
that cell lysis and death are occurring.
“It’s a bit like blood — if you see it on
the floor something bad has
happened,” says Srivastava. After first
evolving to deal with stresses to single
prokaryotic cells, hsps may have
become an intercellular alert signal for
multicellular organisms. As the most
abundant intracellular proteins, hsps
are certainly well suited to the job,
and their peptide-binding means that
they can carry the antigens of
invading infectious agents with them.
Making a product
In 1997, Srivastava prepared doses of
the hsp gp96 from mouse tumors.
When given back to the donor mice,
the gp96 (with peptides still
attached) reduced by tenfold the
number of metastases from a large
tumor. If the large mass was removed
first, otherwise untreated mice died
of micrometastases, but additional
gp96 treatment resulted in symptom-
free survival in 80% of the mice.
Before Antigenics could start
treating people they needed an
efficient means of producing a
personalized therapy. In the current
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procedure, a patient’s tumor sample is
rushed by courier to Antigenics,
where it is passed, in a ten-hour
procedure, through a blender, a
centrifuge, an affinity column and an
ion-exchange column. The final
preparation of hsps and associated
peptides is 80–95% pure. This
preparation is then administered to
the patient over the following weeks.
Immunizing with such a poorly
defined set of peptides raises concerns
about reproducibility. “That has
regulatory implications,” says
Biomira’s Longenecker. “Big pharma
won’t touch that.” Srivastava says that
regulatory agencies “have not
encountered a procedure like this but
they have been extremely helpful and
cooperative. They have been
extremely understanding about the
novelty of it.”
Meanwhile, human studies are
tending to confirm findings in animals
that the treatment does not induce its
own problems. “We do not break
tolerance or induce tolerance,” says
Srivastava. “We’re immunizing with
the whole gemish of molecules but
we only get a specific response. The
prospect of doing harm is not there
based on the human data thus far.”
Srivastava notes that the immune
system is constantly exposed to self
peptides without generating
autoimmunity. Of course, it also fails
to generate immunity to the tumor
antigens without the help of the
immunization procedure. This failure
may be a result of immunosuppressing
factors produced by many tumors, and
the inaccessibility of hsps trapped
inside the tumor cells. Once the hsps
are administered as a treatment, they
become a highly efficient natural
adjuvant. “The receptor [for hsps]
makes it possible,” says Srivastava.
“That is the magical element.”
Antigenics is now in phase I and
II trials for treatment of a number of
different cancers, and financing of
further trials will be helped by the
company’s successful public offering
on February 4. Early trial results have
been promising. For now the choice
of cancer type reflects issues such as
the relative inadequacy of current
treatments and the logistics of patient
recruitment. But Srivastava’s long-
term plans are more ambitious.
“Once we’ve proven that it works,
we’ll essentially expand to every
tumor type,” he says. “Experimental
work suggests there is no limitation.”
The search for the ultimate antigen
Antigenics is in a crowded field (Table
1), but its methods are unique. “The
whole Antigenics approach is based on
the idea that each person’s cancer has
its own antigenic signature,” says
cancer immunologist Drew Pardoll
(Johns Hopkins University, Baltimore,
MD). “In most mouse models that
seems to be the case. The jury is still
out for human cancer.”
Other companies are immunizing
with specific antigens, but
“ultimately the antigens that will be
most useful have not really been
identified,” says Pardoll. “Most of the
vaccines in play don’t use true tumor-
specific antigens,” he says, relying
instead on tissue-specific antigens, or
antigens from viruses associated with
the cancer. In fact, Pardoll says, “true
tumor-specific antigens are unlikely
[to exist]. But the prospects for
getting antigens that are highly
expressed in tumors are pretty good.
I’m optimistic there will be a pretty
good [therapeutic] window.”
Genzyme Molecular Oncology
(Framingham, MA) is using high-
throughput methods to identify
promising antigens — after harvesting
T cells from tumors they test the
T cells for binding to a combinatorial
library of peptides. Bruce Roberts,
Genzyme’s senior director for gene
therapy, agrees that the search for
specific mutations is largely a waste of
time. “I think the thing that is more
reliable is the upregulation of
proteins,” he says. “Cancer cells will
figure out a way to switch on a protein
that will give them a growth
advantage,” he says, and the poor
regulation of that switch can create an
excellent target. Thus the Her2
protein is found in normal epithelial
cells, but its gross overexpression in
some breast cancers makes the
tumors susceptible to Herceptin, a
humanized monoclonal antibody
made by Genentech, Inc. (South
San Francisco, CA).
Perhaps there are single antigens
that will make good targets, and
perhaps the only viable approach will
be individualized therapy. For the
consumer, at least, it is heartening
that both approaches are being
pursued vigorously.
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Table 1
Some of the other companies investigating cancer immunotherapy.
Company Technology and status of trials
StressGen Biotechnologies Corp. Mycoplasma Hsp fused to human papilloma virus antigen, in
phase II trials for treatment of anal and cervical dysplasia. 
Corixa Corporation Lysed melanoma cells plus an adjuvant, now approved for 
use in Canada.
Therion Biologics Corporation Gene therapy with carcinoembryonic antigen for colorectal 
and lung cancer, melanosome antigens including tyrosinase 
for melanoma, PSA for prostate cancer, and mucin for 
breast cancer. Partnership with Pasteur Mérieux Connaught.
Biomira Inc. Synthetic mimic of altered mucin carbohydrate in phase III 
trials for breast cancer. Mucin peptide vaccine (against 
epitope exposed by altered carbohydrate metabolism) in 
phase II for small cell lung cancer.
ImClone Systems Incorporated Ganglioside mimic in phase III for small cell lung carcinoma.
Genzyme Molecular Oncology Gene therapy with melanoma antigens in phase I/II.
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